

EMPOWER EXPANDS ITS ONLINE EDUCATION WITH THE SUPPORT OF EUROLIFE TO PROMOTE THE BENEFITS OF FUNCTIONAL MUSHROOMS AND PSILOCYBIN TO POSITIVELY IMPACT HEALTH AND WELLNESS

VANCOUVER B.C. May 27th, 2020 – EMPOWER CLINICS INC. (CSE: CBDT) (OTC: EPWCF) (Frankfurt 8EC) (“**Empower**” or the “**Company**”), a vertically integrated life sciences company, is pleased to announce that further to the definitive agreement announced on May 15th, 2020 the Company is forming a global mushroom education initiative with EuroLife Brands (“EuroLife”) that will leverage the canvas.me platform.

The new initiative expands the original agreement by formalizing a cloud-based, globally accessible, leading educational experience for patients, clinics, and academic circles to participate, learn, interact, and create information on the uses, treatments, and applications of mushrooms for health and wellness. The global initiative will be positioned as an educational platform but will also accept clinical trial results, integrate with universities and academic circles, provide knowledge and a safe learning experience free from the outside influence of misinformation.

"Our global mushroom education initiative will provide significantly more information pertaining to the treatment of a number of ailments using plant-based treatment options," said Steven McAuley, chairman and chief executive officer of Empower. "We are proud to bring premium health and wellness products to our patients online and in our clinics and mushrooms are already a part of our expanding product line in this category. We look forward to working with the team at EuroLife to launch this initiative in the very near future."

"We have an opportunity to be one of the first online education platforms to deliver information on the benefits of using mushrooms for nutrition and health and wellness," said Shawn Moniz, Chief Executive Officer, EuroLife Brands Inc. "Our [Canvas.me](https://www.canvas.me) education portal is scalable and provides quick and easy access to Empower employees, medical professionals and retail consumers who are in need of this important information. We will continue to leverage our technology to move EuroLife forward."

A report produced by Research and Markets estimates the global mushroom market was over US\$38 billion in 2017 and forecasted to expand at a CAGR of 7.9 per cent from 2018 to 2026. Increasing consumer awareness regarding the health benefits offered by mushrooms is a key factor influencing the growth of the mushroom market at present. Consumer mushroom consumption in supermarkets, restaurants, hotels, and cafeterias are also expected to add to the market demand. Mushrooms are considered a super food as they contain protein, vitamins, minerals and antioxidants, with a great deal of nutritional value and micronutrients. They are low in carbohydrates, high in fiber, and a good source of B-vitamins (riboflavin, pantothenic acid, and niacin), iron, and selenium.

EuroLife and Empower will create a mushroom portal which will leverage the same technology platform used for EuroLife's cannabis portal and will include educational modules on a wide range of topics. The platform will also incorporate dynamic and interactive elements to facilitate learning.

ABOUT EMPOWER

Empower is a vertically integrated health & wellness company with a network of corporate and franchised health & wellness clinics in the U.S. The Company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options.

About EuroLife Brands Inc.

EuroLife Brands (CSE: EURO) (FSE: 3CMA) (OTCPK: EURPF) is a vertically integrated enterprise focused on the pan-European health and wellness sector.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley
Chairman & CEO
s.mcauley@empowerclinics.com
604-789-2146

Investors: Dustin Klein
SVP, Business Development
dustin@svmmjcc.com
720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: rs@maricom.ca, T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain "forward-looking statements" or "forward-looking information" (collectively "forward looking statements") within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as "plans", "continues", "expects", "projects", "intends", "believes", "anticipates", "estimates", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include statements regarding: the Company's expected timing of filing of its Annual Filings, the Company's intention to create psilocybin and psychedelics divisions, that market research on advancements in psilocybin and psychedelics in North America and globally will create greater shareholder value, the Company's intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower's patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company's patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond; the ability of the Company to complete or execute phases One, Two, Three or Four of COVID-19 test programs, and Psychedelic substances remain illegal in most countries, so please reference your local laws in relation to medical or recreational use. Such statements are only projections, are based on assumptions known to management at this

time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company's business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company's control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.